Solutions to the US Food and Drug Administration's separate, but related problems with cannabinoids used as dietary ingredients and with the dietary supplement industry's regulatory compliance should come in the same legislation, suggest former senior agency official Joshua Sharfstein and public health researcher Pieter Cohen.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?